Bioavailability of Dutasteride/Tamsulosin FDC vs Co-administration in Healthy Males

Phase 1, randomised, open-label trial of dutasteride and tamsulosin in benign prostatic hyperplasia (BPH) (2 cohorts), sponsored by GSK. Primary endpoints: Area under the curve from 0 to the time of the last quantifiable concentration of tamsulosin in serum at 72 hours, Area under the curve from 0 to infinity of tamsulosin in serum at 72 hours and 2 more. Started Jul 2014; status: completed.